Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Subgroup returned 37 record(s)
|
|
Sunday, 07/31/2016
|
A Subgroup Identification Method Based on Quantitative Criteria
Yan Sun, AbbVie; Samad Hedayat, University of Illinois at Chicago
2:05 PM
|
On Weighted Performance Goals in Medical Device Single-Arm Clinical Studies
Nelson LU, FDA/CDRH; Yunling Xu, FDA/CDRH
2:50 PM
|
Adaptive Sampling for Subgroup Analyses
Alexander Luedtke, University of California at Berkeley; Antoine Chambaz, L'Université Paris Ouest Nanterre
3:05 PM
|
Individualized Subgroup Variable Selection
Xiwei Tang, University of Illinois at Urbana-Champaign; Annie Qu, University of Illinois at Urbana-Champaign
3:20 PM
|
Comparing Parametric and Semiparametric Bayesian Models for Subgroup Analysis in Clinical Trials
Margaret Gamalo-Siebers, Eli Lilly and Company
4:20 PM
|
Incorporation of Individual Patient Data in Network Meta-Analysis for Multiple Continuous Endpoints, with Application to Diabetes Treatment
Hwanhee Hong, Johns Hopkins Bloomberg School of Public Health; Haoda Fu; Karen Price, Eli Lilly and Company; Bradley Carlin, University of Minnesota
4:45 PM
|
Comparing Novel Approaches to Subgroup Analysis in Early-Phase Clinical Trials
Marius Thomas, Novartis; Björn Bornkamp, Novartis
5:20 PM
|
|
Monday, 08/01/2016
|
Subgroup Analyses for Count Data Using Bayesian Empirical Meta-Analytical Predictive Priors
Wei-Chen Chen, FDA/CBER; Judy X. Li, FDA; John Scott, FDA
|
A STEPP Forward in Tailoring Treatment: New Research on the STEPP Methodology
Wai-Ki Yip, Dana-Farber Cancer Institute
|
A STEPP Forward in Tailoring Treatment: New Research on the STEPP Methodology
Wai-Ki Yip, Dana-Farber Cancer Institute
10:10 AM
|
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Jaya M. Satagopan, Memorial Sloan Kettering Cancer Center; Alexia Iasonos, Memorial Sloan Kettering Cancer Center
10:35 AM
|
Overcoming Computational Challenges of Subgroup Identification Using SIDES Method
Ilya Lipkovich, Quintiles; Alex Dmitrienko, Quintiles
2:05 PM
|
Randomization does not prevent bias when we assess treatment by covariate interaction
Lei Nie, FDA; Zhiwei Zhang, FDA/CDRH; Jialu Zhang, FDA
2:05 PM
|
Precision Medicine: How Bayesian Empirical Subgroup Analysis Plays a Role
Judy X. Li, FDA; Wei-Chen Chen, FDA/CBER; John Scott, FDA
3:05 PM
|
Bayesian Bounding of the Population Subgroup Which Benefits from Treatment
Patrick Schnell, University of Minnesota; Qi Tang, AbbVie; Walt Offen, AbbVie; Bradley Carlin, University of Minnesota
3:05 PM
|
|
Wednesday, 08/03/2016
|
Properties of Adaptive Clinical Trial Signature Design in the Presence of Gene and Gene-Treatment Interaction
Alexander Cambon, University of Louisville; Shesh N. Rai, University of Louisville; Guy Brock, University of Louisville
|
Estimation After Adaptive Population Enrichment Design
Vlad Dragalin, Janssen
8:35 AM
|
Subgroup Analyses in Early-Phase Clinical Trials: Challenges and Opportunities
Björn Bornkamp, Novartis; Marius Thomas, Novartis
8:35 AM
|
Visualizing the Limitations of Subgroup Analyses
Kevin Andrew Buhr, University of Wisconsin - Madison
8:55 AM
|
Subgroup Analysis in Regulatory Decision Making
Lilly Yue, FDA/CDRH/OSB
9:15 AM
|
Visualization vs traditional presentation of data - what is there in subgroups?
Vipin Arora, Eli Lilly and Company
9:35 AM
|
Modeling the Effects of Network Attributes on Subgroup Integration
Qiwen Zheng, University of Maryland
11:00 AM
|
Case Studies in Academic-Industry-Government Collaborations in Bayesian Adaptive Clinical Trials
Bradley Carlin, University of Minnesota
2:05 PM
|
Optimizing Dynamic Treatment Regimes via Quality-Adjusted Q-Learning and Threshold Utility Analysis for Subgroup Analysis in Clinical Trials
Geoffrey Johnson; Andrew Topp, University of Pittsburgh; Abdus S. Wahed, University of Pittsburgh
2:50 PM
|
Cross-Validated STEPP Analysis for Biomarker Subgroup Determination Problems
Gu Mi, Eli Lilly and Company; Tuan Stevon Nguyen, Eli Lilly and Company; Jonathan Denne, Eli Lilly and Company
3:20 PM
|
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation
Ailin Fan, North Carolina State University; Rui Song, North Carolina State University; Wenbin Lu, North Carolina State University
3:20 PM
|
Efficient Discovery of Heterogeneous Treatment Effects in Randomized Experiments via Anomalous Pattern Detection
Edward McFowland, Carlson School of Management; Sriram Somanchi, University of Notre Dame; Daniel B. Neill, Carnegie Mellon University
3:35 PM
|
|
Thursday, 08/04/2016
|
Use of the VG (Virtual Twins Combined with GUIDE) Method in the Development of Precision Medicines
Jia Jia; Qi Tang, AbbVie; Wangang Xie, AbbVie; Richard A. Rode, AbbVie
8:35 AM
|
Comparison of Some Subgroup Identification Algorithms for Precision Medicine in Drug Development
Xin Huang; Yan Sun, AbbVie; Saptarshi Chatterjee, AbbVie; Viswanath Devanarayan, AbbVie
8:55 AM
|
Subgroup Identification Based on Multiple Outcomes
Chensheng Kuang, University of Wisconsin - Madison; Menggang Yu, University of Wisconsin - Madison; Sijian Wang, University of Wisconsin - Madison
9:15 AM
|
Development of Predictive Signature to Identify Patient Subgroups with Differential Treatment Effect
Yu-Chuan Chen; James Chen, FDA/NCTR; Un Jung Lee, FDA/NCTR
9:35 AM
|
Subgroup Identification and Sample-Size Calculation for the Proportional Hazard Model
Suhyun Kang, North Carolina State University ; Wenbin Lu, North Carolina State University
9:35 AM
|
Patient Subgroup Identification in Clinical Trials Where Overall Treatment Response Is Suboptimal
Isaac Nuamah, Janssen R&D; Youping Huang, Janssen R&D
9:50 AM
|
Subgroup Identification in a Learn-and-Confirm Setting
Lei Shen, Eli Lilly and Company
9:55 AM
|
|
|
